山西仟源医药集团股份有限公司 证券代码：300254 证券简称：仟源医药 公告编号：2025-060 关于回购注销限制性股票减少注册资本暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日召开第五 届董事会第三十一次会议；并于 2025 年 8 月 26 日召开了 2025 年第四次临时股东会，审 议通过了《关于回购注销 2024 年限制性股票激励计划部分限制性股票的议案》、《关于 变更注册资本、修订<公司章程>并办理工商变更登记的议案》。公司 2024 年限制性股票 激励计划首次授予的激励对象中有 1 名激励对象因离职已不具备激励对象资格，其已 获授予但尚未解除限售的 6.00 万股限制性股票将由公司办理回购注销，具体内容详见 公司披露在巨潮资讯网（www.cninfo.com.cn）的相关公告。 公司本次回购注销限制性股票导致总股本及注册资本减少，公司总股本由 248,318,563 股减少至 248,258,563 股，公司注册资本由 248,318,563 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.33% on August 26, with Yuan Dong Biological leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haixiang Pharmaceutical (002099) with a closing price of 6.41, up 6.13% [1] - ST Suwu (600200) with a closing price of 1.11, up 4.72% [1] - Maiwei Biological (688062) with a closing price of 42.50, up 4.14% [1] - Major decliners included: - Yuan Dong Biological (688513) with a closing price of 63.08, down 10.71% [2] - Guangsheng Tang (300436) with a closing price of 138.88, down 8.60% [2] - Shutaishen (300204) with a closing price of 56.70, down 7.05% [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 30.51 billion yuan from institutional investors, while retail investors contributed a net inflow of 18.08 billion yuan [2] - The sector's capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Haixiang Pharmaceutical (002099) had a net inflow of 78.77 million yuan from institutional investors, while retail investors saw a net outflow of 77.68 million yuan [3] - Other notable stocks with significant capital flows included: - Borui Pharmaceutical (688166) with a net inflow of 78.36 million yuan from institutional investors [3] - Yifang Biological (688382) with a net inflow of 28.31 million yuan from institutional investors but a net outflow of 89.39 million yuan from retail investors [3]

证券代码：300254 证券简称：仟源医药 公告编号：2025-058 山西仟源医药集团股份有限公司 2025年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》、《上市公司募集资金监管规则》、《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》以及《深圳证券交易 所创业板上市公司自律监管指南第 2 号——公告格式》等有关规定，山西仟源医 药集团股份有限公司（以下简称"公司"或"本公司"）董事会编制了 2025 年半 年度募集资金存放、管理与使用情况的专项报告，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 1、2020 年度向特定对象发行股票募集资金金额、资金到位情况 经中国证券监督管理委员会《关于同意山西仟源医药集团股份有限公司向特 定对象发行股票注册的批复》（证监许可〔2020〕2273 号）批复，公司以简易程 序向 2 名特定对象发行人民币普通股（A 股）19,6 ...

山西仟源医药集团股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表（一） 单位：万元 其它关联资金往来 资金往来方名称 往来方与上 市公司的关 联关系 上市公司核算 的会计科目 2025 年期初 往来资金余额 2025年1-6月往 来累计发生金额 （不含利息） 2025 年 1-6 月 往来资金的利 息（如有） 2025年1-6月 偿还累计发 生金额 2025 年 6 月末 往来资金余额 往来形 成原因 往来性质 （经营性往来、 非经营性往来） 控股股东、实际控制 人及其附属企业 上市公司的子公司及 其附属企业 西藏仟源药业 有限公司 子公司 应收账款 9,791.09 3,657.28 4,394.68 9,053.69 销售货 款 经营性往来 西藏仟源药业 有限公司 子公司 其他应收款 2,193.78 2,965.72 5,159.50 - 往来款、 代缴社 保 非经营性往来 南通恒嘉药业 有限公司 子公司 其他应收款 5.00 5.00 借款 非经营性往来 南通广嘉医药 有限公司 子公司 其他应收款 690.00 690.00 借款 非经营性往来 其他关联方及其附属 企业 四 ...

2025年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司《2025年半年度报告全文》及其摘要已于 2025 年 8 月 26 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露，敬请广大投资者注意查阅。 证券代码：300254 证券简称：仟源医药 公告编号：2025-056 山西仟源医药集团股份有限公司 山西仟源医药集团股份有限公司 董事会 二〇二五年八月二十六日 特此公告 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-055 山西仟源医药集团股份有限公司 第五届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日以邮件方式发出第五届董事会第三十二次会议通知及议案，2025 年 8 月 25 日 以通讯表决的方式召开本次会议。本次会议由董事长黄乐群先生主持，应出席董 事 9 名，实际出席董事 9 名。出席会议人员对本次会议的召集、召开方式无异议。 本次会议的召集、召开符合《公司法》、《公司章程》和《董事会议事规则》的有 关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以投票表决 方式通过以下议案： 1、审议通过《关于公司<2025 年半年度报告全文>及其摘要的议案》 经审议，与会董事同意：公司严格按照《公司法》、《证券法》、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《深圳证券交 易所创业板上市公司自律监管指 ...

南财智讯8月25日电，仟源医药发布2025年半年度报告，报告期实现营业收入3.73亿元，同比下降 7.01%；归属上市公司股东的净利润38.09万元，同比下降98.86%；扣除非经常性损益后的归属于上市公 司股东的净利润-501.17万元，同比下降124.99%；基本每股收益0.0016元。 ...

[Section I Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Section%20I%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides crucial disclaimers, outlines the report's structure, lists reference documents, and defines key terms for clarity [Important Notice](index=2&type=section&id=Important%20Notice) The company's board, supervisory board, and senior management guarantee the report's accuracy, while the financial officers confirm the financial statements' integrity, with all directors attending the review meeting - Company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, free from false records, misleading statements, or major omissions[4](index=4&type=chunk) - Company's responsible person Zhao Qun, head of accounting work He Yanjie, and head of accounting department Liu Yali declare that the financial report is true, accurate, and complete[4](index=4&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[5](index=5&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) The report's clear table of contents lists eight main chapters covering important notices, company profile, MD&A, corporate governance, significant matters, share changes, bond information, and financial reports, with page numbers indicated - The report comprises **eight main chapters**, structured clearly for easy reference[7](index=7&type=chunk) - Chapter content covers company overview, financial performance, management analysis, corporate governance, significant events, and financial reports[7](index=7&type=chunk) [List of Reference Documents](index=4&type=section&id=List%20of%20Reference%20Documents) Reference documents include financial statements signed and sealed by the legal representative and accounting officers, original announcements disclosed on the CSRC-designated website, and the original semi-annual report, all available at the company's securities department - Reference documents include financial statements bearing the signatures and seals of the company's legal representative, head of accounting work, and head of accounting department[9](index=9&type=chunk) - All original company documents and announcements publicly disclosed on the CSRC-designated website during the reporting period are also included in the reference documents[10](index=10&type=chunk) - These documents are available at the company's securities department[13](index=13&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines common terms used in the report, including company names, key subsidiaries, governance bodies, and industry-specific medical terminology, ensuring accurate understanding of the content - "Company", "the Company", and "Qianyuan Pharmaceutical" all refer to Shanxi Qianyuan Pharmaceutical Group Co., Ltd[15](index=15&type=chunk) - Several holding and wholly-owned subsidiaries are listed, such as Qianyuan Haisheng, Baoling Group, and Qianyuan Enshi[15](index=15&type=chunk) - Medical industry specific terms like "generic drugs", "anti-infective drugs", "gene preservation", "GMP", and "consistency evaluation" are explained[15](index=15&type=chunk) [Section II Company Profile and Key Financial Indicators](index=6&type=section&id=Section%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides an overview of the company's basic information, contact details, and a summary of its key financial performance and indicators for the reporting period [I. Company Profile](index=6&type=section&id=I.%20Company%20Profile) The company, Shanxi Qianyuan Pharmaceutical Group Co., Ltd., is listed on the Shenzhen Stock Exchange under stock code 300254, with Zhao Qun as its legal representative - Company stock abbreviation: Qianyuan Pharmaceutical, stock code: **300254**[17](index=17&type=chunk) - Stock exchange for listing: Shenzhen Stock Exchange[17](index=17&type=chunk) - The company's legal representative is Zhao Qun[17](index=17&type=chunk) [II. Contact Persons and Information](index=6&type=section&id=II.%20Contact%20Persons%20and%20Information) The company's Board Secretary is Yu Junxian and Securities Affairs Representative is Xue Yuanyuan, both located at No. 2 Cuiwei Street, Datong Economic and Technological Development Zone, with provided contact details - Board Secretary is Yu Junxian, Securities Affairs Representative is Xue Yuanyuan[18](index=18&type=chunk) - Contact address: No. 2 Cuiwei Street, Biotechnology Innovation Industrial Park, Datong Economic and Technological Development Zone[18](index=18&type=chunk) - Contact phone: **0352-6116426**, fax: **0352-6116452**[18](index=18&type=chunk) [III. Other Information](index=6&type=section&id=III.%20Other%20Information) During the reporting period, there were no changes in the company's registered address, office address, website, email, information disclosure website, media name, or registration status, with details available in the 2024 annual report - The company's registered address, office address and postal code, website, email, etc., remained unchanged during the reporting period[19](index=19&type=chunk) - Information disclosure and availability locations remained unchanged during the reporting period[20](index=20&type=chunk) - The company's registration status remained unchanged during the reporting period[21](index=21&type=chunk)[22](index=22&type=chunk) [IV. Key Accounting Data and Financial Indicators](index=7&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) This reporting period saw a **7.01% decrease** in operating revenue, a **98.86% significant drop** in net profit attributable to shareholders, a **124.99% decline** in non-recurring net profit, and a **62.82% decrease** in net cash flow from operating activities, alongside reductions in total assets and net assets Key Accounting Data and Financial Indicators | Indicator | Current Reporting Period (Yuan) | Prior Year Period (Yuan) | Change from Prior Year Period | | :--- | :--- | :--- | :--- | | Operating Revenue | 372,995,932.54 | 401,112,573.00 | -7.01% | | Net Profit Attributable to Shareholders of Listed Company | 380,868.67 | 33,502,484.50 | -98.86% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Gains/Losses) | -5,011,716.56 | 20,055,202.16 | -124.99% | | Net Cash Flow from Operating Activities | 22,483,410.56 | 60,473,663.78 | -62.82% | | Basic Earnings Per Share (Yuan/share) | 0.0016 | 0.1387 | -98.85% | | Diluted Earnings Per Share (Yuan/share) | 0.0016 | 0.1387 | -98.85% | | Weighted Average Return on Net Assets | 0.14% | 5.43% | -5.29% | | **End of Current Reporting Period (Yuan)** | **End of Prior Year (Yuan)** | **Change from End of Prior Year** | | | Total Assets | 1,496,381,241.42 | 1,547,725,078.17 | -3.32% | | Net Assets Attributable to Shareholders of Listed Company | 253,595,732.99 | 342,998,882.45 | -26.07% | - Net profit after deducting the impact of share-based payments was **7,576,850.54 Yuan**[23](index=23&type=chunk) [V. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=7&type=section&id=V.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) During the reporting period, the company reported no differences in net profit and net assets between financial statements prepared under international or overseas accounting standards and those prepared under Chinese accounting standards - The company reported no differences in net profit and net assets between financial statements disclosed under international accounting standards and those under Chinese accounting standards during the reporting period[24](index=24&type=chunk) - The company reported no differences in net profit and net assets between financial statements disclosed under overseas accounting standards and those under Chinese accounting standards during the reporting period[25](index=25&type=chunk) [VI. Non-recurring Gains and Losses and Their Amounts](index=8&type=section&id=VI.%20Non-recurring%20Gains%20and%20Losses%20and%20Their%20Amounts) Total non-recurring gains and losses for the current period amounted to **5,392,585.23 Yuan**, primarily from disposal of non-current assets, government grants, and capital occupation fees, while certain recurring government grants were classified as ordinary income Non-recurring Gains and Losses and Their Amounts | Item | Amount (Yuan) | Explanation | | :--- | :--- | :--- | | Gains or losses from disposal of non-current assets (including the write-off portion of asset impairment provisions) | 7,755,156.75 | | | Government grants recognized in current profit or loss (excluding those closely related to the company's normal operations, compliant with national policies, enjoyed according to fixed standards, and having a continuous impact on the company's profit or loss) | 994,930.43 | | | Capital occupation fees charged to non-financial enterprises recognized in current profit or loss | 113,207.54 | | | Reversal of impairment provisions for individually tested receivables | 2,500.00 | | | Other non-operating income and expenses apart from the above items | -4,255,800.81 | | | Less: Income tax impact | -551,202.03 | | | Minority interest impact (after tax) | -231,389.29 | | | **Total** | **5,392,585.23** | | - The company classified government grants closely related to normal business operations, compliant with national policies, enjoyed according to fixed standards, and having a continuous impact on the company's profit or loss (**10,401,989.65 Yuan** for January-June 2025) as recurring gains and losses[27](index=27&type=chunk) [Section III Management Discussion and Analysis](index=9&type=section&id=Section%20III%20Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's primary business operations, core competencies, financial performance, investment activities, and the risks and opportunities it faces [I. Main Business Activities During the Reporting Period](index=9&type=section&id=I.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company primarily engages in R&D, production, and sales of pharmaceuticals and health foods, along with medical diagnostic and gene preservation services, experiencing a **7.01% revenue decline** and a **98.86% net profit drop** due to tax adjustments, reduced gross profit, and increased equity incentive expenses - The company operates in the pharmaceutical industry, primarily engaged in the R&D, production, and sales of pharmaceuticals and health foods, as well as medical diagnostic, gene preservation, and commercial services[29](index=29&type=chunk) Company's Main Financial Performance in H1 2025 | Indicator | Amount (10,000 Yuan) | Year-on-year Change | | :--- | :--- | :--- | | Operating Revenue | 37,299.59 | -7.01% | | Net Profit Attributable to Shareholders of Listed Company | 38.09 | -98.86% | - The decline in performance was mainly due to a subsidiary's supplementary payment of corporate income tax and late fees, a decrease in gross profit due to lower operating revenue, and an increase in equity incentive expenses year-on-year[32](index=32&type=chunk) [1. Company's Main Business](index=9&type=section&id=1.%20Company's%20Main%20Business) The company's core business encompasses R&D, production, and sales of pharmaceuticals and health foods, alongside medical diagnostic and gene preservation services, offering a diverse range of pharmaceutical products and key health food items like Baoling Yunbao Oral Liquid - The company operates in the pharmaceutical industry, primarily engaged in the R&D, production, and sales of pharmaceuticals and health foods, as well as medical diagnostic, gene preservation, and commercial services[29](index=29&type=chunk) - Pharmaceutical product categories include anti-infective drugs, anti-allergic drugs, urinary system drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, antidepressant drugs, kidney disease drugs, pharmaceutical raw materials, and intermediates[29](index=29&type=chunk) - The company's health food products primarily include Baoling Yunbao Oral Liquid, and medical health services include medical testing and gene preservation services[29](index=29&type=chunk) [2. Company's Main Products and Their Uses](index=9&type=section&id=2.%20Company's%20Main%20Products%20and%20Their%20Uses) The company's product portfolio includes anti-infective, anti-allergic, urinary system, smoking cessation, pediatric, respiratory, antidepressant, kidney disease, novel oral anticoagulant, and antihypertensive drugs, along with health foods and DNA gene preservation services, each with specific indications or uses Company's Main Products and Their Uses | Therapeutic Area | Product Name | Product Use | | :--- | :--- | :--- | | Anti-infective Drugs | Fosfomycin Trometamol Granules | Used for respiratory tract infections, lower urinary tract infections (such as cystitis, urethritis), intestinal infections, and skin and soft tissue infections caused by susceptible pathogens | | Anti-allergic Drugs | Ebastine Tablets | Indicated for allergic rhinitis with or without allergic conjunctivitis; symptomatic treatment of chronic idiopathic urticaria | | Urinary System Drugs | Tamsulosin Hydrochloride Extended-Release Capsules | Urinary obstruction caused by benign prostatic hyperplasia | | Smoking Cessation Drugs | Varenicline Tartrate Tablets | Indicated for smoking cessation in adults | | Pediatric Drugs | Montmorillonite Powder | Indicated for acute and chronic diarrhea in adults and children | | Pediatric Drugs | Vitamin AD Drops | Indicated for the prevention and treatment of vitamin A and D deficiencies | | Respiratory System Drugs | Ambroxol Hydrochloride Dispersible Tablets | Indicated for the treatment of acute and chronic respiratory diseases with abnormal sputum secretion and impaired sputum clearance | | Antidepressant Drugs | Fluoxetine Hydrochloride Capsules | Indicated for depression, obsessive-compulsive disorder, bulimia nervosa: as an adjunct to psychotherapy to reduce binge eating and purging behaviors | | Antidepressant Drugs | Sertraline Hydrochloride Tablets | Used for the treatment of symptoms associated with depression, including伴随焦虑、有或无躁狂史的抑郁症。疗效满意后，继续服用可有效地防止抑郁症的复发和再发。也用于治疗强迫症。疗效满意后，继续服用舍曲林可有效地防止强迫症初始症状的复发。 | | Kidney Disease Drugs | Cinacalcet Hydrochloride Tablets | Used for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients undergoing dialysis, and also for hypercalcemia in patients with parathyroid carcinoma | | Novel Oral Anticoagulants | Apixaban Tablets | Primarily used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE); used for the treatment of adult deep vein thrombosis (DVT) and pulmonary embolism (PE); used in adult patients with non-valvular atrial fibrillation with one or more risk factors to reduce the risk of stroke and systemic embolism | | Novel Oral Anticoagulants | Rivaroxaban Tablets | Primarily used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism (VTE) | | Antihypertensive Drugs | Perindopril Arginine Tablets | Indicated for the treatment of all types of hypertension and heart failure | | Health Foods | Baoling Brand Yunbao Oral Liquid | Improves nutritional anemia, enhances immunity | | Services | DNA Gene Preservation | Primarily used as raw material for gene therapy, assisting in disease diagnosis and treatment | [3. Company's Business Model](index=10&type=section&id=3.%20Company's%20Business%20Model) The company operates on a "production-to-order" model, adhering strictly to GMP standards, with centralized procurement, and a sales strategy combining distributors and promotional service providers for pharmaceuticals, primarily distributors for health foods, and direct sales for raw materials and services - Procurement Model: The procurement department is solely responsible, with bulk items centralized procured, strict selection and assessment of suppliers, and reasonable control of procurement inventory[31](index=31&type=chunk) - Production Model: Adopts a "production-to-order" approach, where the production department arranges production based on sales plans, strictly adhering to GMP requirements to ensure product quality and safety[31](index=31&type=chunk) - Sales Model: Pharmaceutical preparations use a combination of distributor sales and academic promotion by service providers; health foods are primarily sold through distributors with supplementary direct sales; raw materials and service businesses mainly adopt a direct sales model[31](index=31&type=chunk) [4. Company's Key Operations During the Reporting Period](index=10&type=section&id=4.%20Company's%20Key%20Operations%20During%20the%20Reporting%20Period) In H1 2025, the company's operating revenue was **372.99 million Yuan**, a **7.01% decrease**, and net profit attributable to shareholders was **0.38 million Yuan**, a **98.86% decrease**, primarily due to a subsidiary's supplementary tax payments, reduced gross profit, and increased equity incentive expenses, while actively advancing sales, R&D, production, and internal management H1 2025 Key Financial Data | Indicator | Amount (10,000 Yuan) | Year-on-year Change | | :--- | :--- | :--- | | Operating Revenue | 37,299.59 | -7.01% | | Net Profit Attributable to Shareholders of Listed Company | 38.09 | -98.86% | - The decline in performance was mainly due to a subsidiary's supplementary payment of corporate income tax and late fees, a decrease in gross profit due to lower operating revenue, and an increase in equity incentive expenses year-on-year[32](index=32&type=chunk) - The company focused on market growth breakthroughs in sales, accelerated the layout of first-generic drug commercialization in R&D, strengthened basic management and promoted energy saving and process optimization in production, and enhanced management efficiency through digitalization and compliance in internal management[32](index=32&type=chunk)[33](index=33&type=chunk)[34](index=34&type=chunk) [5. Industry Development Overview](index=10&type=section&id=5.%20Industry%20Development%20Overview) In 2025, the pharmaceutical industry is transitioning from policy-driven growth to intrinsic value, with expanding development space driven by an aging population and health consumption upgrades, while national regulations optimize review processes and strengthen supervision, and the company's R&D projects are progressing well - In 2025, the pharmaceutical industry is transforming from "policy dividend-driven" to "intrinsic value-driven", with continuous expansion of industry development space[35](index=35&type=chunk) - The National Medical Products Administration optimized drug and medical device review and approval processes, strengthened full lifecycle supervision, and issued anti-monopoly guidelines to reinforce industry compliance boundaries[35](index=35&type=chunk)[36](index=36&type=chunk) Company's R&D Project Progress During the Reporting Period | No. | Project Name | Registration Category | Indications | Research Progress | | :--- | :--- | :--- | :--- | :--- | | 1 | Ferric Maltol Capsules | Chemical Drug Class 3 | For the treatment of iron deficiency anemia in adults | Clinical trial approval notice obtained | | 4 | Evocalcet Tablets | Chemical Drug Class 4 | Treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on maintenance dialysis | Drug registration acceptance notice obtained | | 8 | Ebastine API | - | Used for allergic rhinitis with or without allergic conjunctivitis; symptomatic treatment of chronic idiopathic urticaria | Chemical API marketing application approval notice obtained in May 2025 | Information on Drugs with Sales Exceeding 10% of the Company's Main Business Revenue in the Reporting Period and Prior Year Period | Drug Name | Indications or Functions | Registration Category | | :--- | :--- | :--- | | Fosfomycin Trometamol Granules | Used for respiratory tract infections, lower urinary tract infections, intestinal infections, and skin and soft tissue infections caused by susceptible pathogens | Chemical Drug Class 6 | | Tamsulosin Hydrochloride Extended-Release Capsules | Used for urinary obstruction caused by benign prostatic hyperplasia | Chemical Drug Class 4 | [II. Analysis of Core Competencies](index=11&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies stem from its "high-end pharmaceutical core, precision medicine and health food wings" strategy, featuring diversified product advantages, a stable self-operated sales team and national marketing network, stringent GMP-compliant quality control, and a strong R&D innovation capability primarily through independent research - The company has established a development strategy centered on "high-end pharmaceuticals as the core, with precision medicine and health foods as wings", offering a product line covering anti-infective drugs, urinary system drugs, smoking cessation drugs, pediatric drugs, and other areas[38](index=38&type=chunk) - The company possesses a stable self-operated sales team and network, employing a market-demand-oriented product marketing strategy, and has established an effective national marketing network through academic conferences and other means[40](index=40&type=chunk) - The company strictly adheres to GMP standards, controlling product quality comprehensively from R&D to after-sales service, and reinforcing routine GMP management through daily monitoring and special inspections[40](index=40&type=chunk) - The company has a professional R&D team and a comprehensive technological innovation system, with most consistency evaluation and generic drug projects developed independently, and has obtained multiple drug registration approvals and API marketing approval notices[41](index=41&type=chunk) [III. Analysis of Main Business Operations](index=12&type=section&id=III.%20Analysis%20of%20Main%20Business%20Operations) During the reporting period, the company's main business operating revenue decreased by **7.01%**, and net profit attributable to shareholders significantly dropped by **98.86%**, primarily due to a subsidiary's supplementary tax payments, increased financial expenses, and higher income tax expenses, with anti-infective and urinary system drugs remaining key revenue drivers Year-on-Year Changes in Key Financial Data | Indicator | Current Reporting Period (Yuan) | Prior Year Period (Yuan) | Year-on-year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 372,995,932.54 | 401,112,573.00 | -7.01% | | | Financial Expenses | 11,826,091.90 | 7,622,780.01 | 55.14% | Mainly due to increased bank loan interest during the reporting period | | Income Tax Expenses | 19,230,101.30 | 1,546,497.51 | 1,143.46% | Mainly due to supplementary payment of prior year income tax and other matters during the reporting period | | Net Cash Flow from Operating Activities | 22,483,410.56 | 60,473,663.78 | -62.82% | Mainly due to increased tax payments and decreased cash received from sales of goods and services during the reporting period | - During the reporting period, subsidiary Tibet Qianyuan made supplementary payments of corporate income tax of **8.4942 million Yuan** and corresponding late fees of **5.5406 million Yuan** for 2019-2023, totaling **14.0348 million Yuan**, impacting the net profit attributable to shareholders by **8.4444 million Yuan** in 2025[44](index=44&type=chunk) Information on Products or Services Accounting for Over 10% of the Company's Main Business Revenue | Product or Service | Operating Revenue (Yuan) | Operating Cost (Yuan) | Gross Margin | Year-on-year Change in Operating Revenue | Year-on-year Change in Operating Cost | Year-on-year Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Anti-infective Drugs | 67,774,360.00 | 14,816,273.98 | 78.14% | -15.21% | -8.80% | -1.54% | | Urinary System Drugs | 103,258,251.36 | 28,046,106.53 | 72.84% | 18.73% | 14.14% | 1.09% | [IV. Analysis of Non-Core Business Operations](index=13&type=section&id=IV.%20Analysis%20of%20Non-Core%20Business%20Operations) Non-core business contributions to total profit primarily came from non-operating income (government support funds) and other income (government grants), while non-operating expenses (late fees and non-current asset write-offs) were the main negative impacts, with investment income and asset impairment having minor effects Impact of Non-Core Business on Total Profit | Item | Amount (Yuan) | Proportion of Total Profit | Reason for Formation | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 113,156.56 | 0.32% | Mainly capital occupation fees received from non-financial enterprises | No | | Asset Impairment | 911,697.76 | 2.56% | Mainly reversal of inventory depreciation provisions | No | | Non-operating Income | 9,024,543.49 | 25.38% | Mainly government support funds received | Yes | | Non-operating Expenses | 4,430,200.21 | 12.46% | Mainly late fees and losses from destruction/scrapping of non-current assets | No | | Other Income | 2,349,598.39 | 6.61% | Mainly various government grants received | No | | Credit Impairment Losses | 510,134.82 | 1.43% | Mainly reversal of bad debt provisions for accounts receivable | No | [V. Analysis of Assets and Liabilities](index=13&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) At the end of the reporting period, total assets decreased by **3.32%** and net assets attributable to shareholders decreased by **26.07%**, with notable changes including reduced monetary funds due to equity transfer payments, increased construction in progress for new factory renovations, and a significant rise in long-term payables from equity repurchase obligations, while **130.95 million Yuan** of assets are restricted by pledges or mortgages Significant Changes in Asset Composition | Item | Amount at End of Current Reporting Period (Yuan) | Proportion of Total Assets | Amount at End of Prior Year (Yuan) | Proportion of Total Assets | Change in Proportion | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 92,408,396.19 | 6.18% | 149,518,040.96 | 9.66% | -3.48% | Mainly due to the company's payment of equity transfer payables during the reporting period | | Inventories | 149,943,038.52 | 10.02% | 132,785,588.91 | 8.58% | 1.44% | | | Construction in Progress | 32,893,176.54 | 2.20% | 15,283,785.93 | 0.99% | 1.21% | Mainly due to new factory renovation projects added by the company | | Other Payables | 83,746,414.44 | 5.60% | 165,307,278.88 | 10.68% | -5.08% | Mainly due to a decrease in the company's equity transfer payables at the end of the reporting period | | Long-term Payables | 226,336,400.00 | 15.13% | 129,356,400.00 | 8.36% | 6.77% | Mainly due to an increase in the company's equity repurchase payables at the end of the reporting period | Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (Yuan) | Amount Purchased in Current Period (Yuan) | Amount Sold in Current Period (Yuan) | Ending Balance (Yuan) | | :--- | :--- | :--- | :--- | :--- | | Receivables Financing | 28,217,773.52 | 90,748,231.00 | 84,674,238.25 | 34,291,766.27 | | **Total Above** | **28,217,773.52** | **90,748,231.00** | **84,674,238.25** | **34,291,766.27** | - As of the end of the reporting period, the total amount of restricted assets was **130,952,244.15 Yuan**, primarily including pledged or frozen monetary funds, intangible assets, investment properties, and fixed assets[53](index=53&type=chunk) - The company's **100% equity** in Hangzhou Baoling Group Co., Ltd., subsidiary Nantong Guangjia Pharmaceutical Co., Ltd.'s **36% equity** in Jiangsu Jiayi Pharmaceutical Co., Ltd., and the company's **30% equity** in Nantong Hengjia Pharmaceutical Co., Ltd. are all restricted due to pledges[53](index=53&type=chunk)[54](index=54&type=chunk) [VI. Analysis of Investment Status](index=15&type=section&id=VI.%20Analysis%20of%20Investment%20Status) The company's investment amount increased by **149.68%** year-on-year, with **228.1251 million Yuan** cumulatively used from two private placements in 2020 and 2021, leaving a balance of **13.5767 million Yuan**, while some fundraising projects were altered or terminated due to market changes or R&D delays, with funds reallocated to new drug R&D or permanent working capital Investment Amount During the Reporting Period | Indicator | Investment Amount in Reporting Period (Yuan) | Investment Amount in Prior Year Period (Yuan) | Change Rate | | :--- | :--- | :--- | :--- | | Investment Amount | 23,039,484.39 | 9,227,675.94 | 149.68% | Overall Use of Raised Funds | Fundraising Year | Fundraising Method | Net Raised Funds (10,000 Yuan) | Total Cumulative Used Raised Funds (10,000 Yuan) | Total Unused Raised Funds (10,000 Yuan) | | :--- | :--- | :--- | :--- | :--- | | 2020 | Private Placement of Shares | 13,358.06 | 12,939.94 | 651.35 | | 2021 | Private Placement of Shares | 10,409.04 | 9,872.57 | 706.32 | | **Total** | | **23,767.10** | **22,812.51** | **1,357.67** | - The R&D progress of "New Drug R&D Project - Roxadustat and Capsules" has been delayed, with the estimated date of reaching its intended usable state extended to December 2026[63](index=63&type=chunk)[68](index=68&type=chunk) - The "Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. Annual Output of 300 Million Tablets Solid Preparation Production Line Technical Transformation Project" has been terminated due to Ebastine Tablets not winning centralized procurement and existing capacity meeting demand, with the remaining raised funds permanently supplementing working capital[63](index=63&type=chunk)[67](index=67&type=chunk)[68](index=68&type=chunk) - Some drug R&D projects were terminated due to the original drug not being approved or intense competition, and the **40.5 million Yuan** R&D investment freed up will be used for other R&D projects[64](index=64&type=chunk)[68](index=68&type=chunk) [VII. Significant Asset and Equity Disposals](index=22&type=section&id=VII.%20Significant%20Asset%20and%20Equity%20Disposals) During the reporting period, the company sold land use rights, properties, and attachments at No. 1378 Heng'an Street, Datong Economic and Technological Development Zone, to Shanxi Shuangyan Pharmaceutical Co., Ltd. for **7.8945 million Yuan** to revitalize assets and optimize its structure, with no significant equity disposals Disposal of Significant Assets | Assets Disposed | Transaction Price (10,000 Yuan) | Related Party Transaction | Counterparty | Impact on Company's Net Profit | Disclosure Date | Disclosure Index | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Land use rights, properties, and buildings/attachments at No. 1378 Heng'an Street, Datong Economic and Technological Development Zone | 789.45 | No | Shanxi Shuangyan Pharmaceutical Co., Ltd. | Favorable for the company to revitalize assets and optimize asset structure | July 03, 2023 | Announcement No.: 2023-057 | - The company had no significant equity disposals during the reporting period[73](index=73&type=chunk) [VIII. Analysis of Major Holding and Participating Companies](index=22&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company's major holding subsidiaries, including Zhejiang Qianyuan Haisheng Pharmaceutical Co., Ltd., Tibet Qianyuan Pharmaceutical Co., Ltd., and Jiangsu Jiayi Pharmaceutical Co., Ltd., significantly impacted the company's net profit during the reporting period, with no acquisitions or disposals of subsidiaries Major Subsidiaries and Participating Companies with Over 10% Impact on Company's Net Profit | Company Name | Company Type | Main Business | Registered Capital | Total Assets (Yuan) | Net Assets (Yuan) | Operating Revenue (Yuan) | Operating Profit (Yuan) | Net Profit (Yuan) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Zhejiang Qianyuan Haisheng Pharmaceutical Co., Ltd. | Subsidiary | Pharmaceuticals | 20 million Yuan | 368,188,305.91 | 245,804,293.61 | 148,692,065.83 | 36,716,957.65 | 29,848,366.55 | | Tibet Qianyuan Pharmaceutical Co., Ltd. | Subsidiary | Pharmaceuticals | 10 million Yuan | 266,804,313.92 | 45,565,338.56 | 208,066,124.93 | 3,811,592.06 | 2,303,853.50 | | Jiangsu Jiayi Pharmaceutical Co., Ltd. | Subsidiary | Pharmaceuticals | 187.72934737 million Yuan | 377,283,654.48 | 282,629,351.22 | 45,049,327.46 | 18,428,549.46 | 15,664,267.04 | - The company neither acquired nor disposed of any subsidiaries during the reporting period[74](index=74&type=chunk) [IX. Information on Structured Entities Controlled by the Company](index=23&type=section&id=IX.%20Information%20on%20Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company did not control any structured entities during the reporting period[75](index=75&type=chunk) [X. Risks Faced by the Company and Countermeasures](index=23&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces risks from industry policies, drug R&D and consistency evaluation, drug price reductions, and rising raw material costs, which it addresses by actively monitoring policy changes, increasing R&D investment, optimizing product structure, and strengthening cost control and lean production - The company faces industry policy risks, such as healthcare reform policies, the "two-invoice system", and centralized procurement, which could significantly impact its operating environment[75](index=75&type=chunk) - The company faces drug R&D and consistency evaluation risks, with the possibility of failure or prolonged cycles for new drug development and generic drug consistency evaluation[75](index=75&type=chunk) - The company faces drug price reduction risks, as national medical insurance cost control and centralized volume-based procurement policies continue to compress drug profit margins[76](index=76&type=chunk) - The company faces risks of rising raw material costs, as increased national requirements for drug production standards and environmental standards may lead to higher raw material prices[76](index=76&type=chunk) - Countermeasures include actively assessing market changes, increasing high-end generic drug R&D investment, optimizing product structure, implementing cost control, and fully adopting lean production[75](index=75&type=chunk)[76](index=76&type=chunk) [XI. Registration Form for Research, Communication, Interview, and Other Activities During the Reporting Period](index=23&type=section&id=XI.%20Registration%20Form%20for%20Research%2C%20Communication%2C%20Interview%2C%20and%20Other%20Activities%20During%20the%20Reporting%20Period) During the reporting period, the company conducted three investor relations activities, including two online platform exchanges and one on-site visit, primarily discussing corporate governance, development strategy, operational status, and the marketing of the smoking cessation drug varenicline tartrate tablets - On April 30, 2025, the company engaged in online platform communication with individual investors, discussing corporate governance, development strategy, and operational status[79](index=79&type=chunk) - On May 15, 2025, the company conducted an on-site visit at its Shanghai office, hosting institutional investors to primarily discuss the marketing of the smoking cessation drug varenicline tartrate tablets[79](index=79&type=chunk) - On May 20, 2025, the company participated in the Shanxi jurisdiction listed companies' online collective investor reception day via an online platform, discussing corporate governance, development strategy, and operational status[79](index=79&type=chunk) [XII. Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=24&type=section&id=XII.%20Formulation%20and%20Implementation%20of%20Market%20Value%20Management%20System%20and%20Valuation%20Enhancement%20Plan) The company did not formulate a market value management system or disclose a valuation enhancement plan during the reporting period - The company has not formulated a market value management system[80](index=80&type=chunk) - The company has not disclosed a valuation enhancement plan[80](index=80&type=chunk) [XIII. Implementation of "Quality and Return Dual Improvement" Action Plan](index=24&type=section&id=XIII.%20Implementation%20of%20%22Quality%20and%20Return%20Dual%20Improvement%22%20Action%20Plan) The company did not disclose an announcement regarding the "Quality and Return Dual Improvement" action plan during the reporting period - The company did not disclose an announcement regarding the "Quality and Return Dual Improvement" action plan[80](index=80&type=chunk) [Section IV Corporate Governance, Environment, and Society](index=25&type=section&id=Section%20IV%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section details changes in the company's directors, supervisors, and senior management, profit distribution plans, implementation of equity incentive plans, environmental information disclosure, and social responsibility initiatives [I. Changes in Company Directors, Supervisors, and Senior Management](index=25&type=section&id=I.%20Changes%20in%20Company%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Supervisory Board Chairman Zhu Haibo and Supervisors Zhang Xuhong and Zhang Hua resigned on May 7, 2025, due to work transfers - Supervisory Board Chairman Zhu Haibo resigned on May 07, 2025, due to work transfer[82](index=82&type=chunk) - Supervisors Zhang Xuhong and Zhang Hua resigned on May 07, 2025, due to work transfer[82](index=82&type=chunk) [II. Profit Distribution and Capital Reserve Conversion to Share Capital in the Current Reporting Period](index=25&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20to%20Share%20Capital%20in%20the%20Current%20Reporting%20Period) The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period[83](index=83&type=chunk) [III. Implementation of Company Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=25&type=section&id=III.%20Implementation%20of%20Company%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) In 2024, the company implemented a restricted stock incentive plan, granting **7.05 million restricted shares** to 50 grantees at **4.73 Yuan/share**, and subsequently repurchased and cancelled **0.35 million shares** due to three grantees' departures, with **6.70 million shares** remaining outstanding under the plan, representing **2.70%** of total share capital - The company reviewed and approved the "2024 Restricted Stock Incentive Plan (Draft)" and its summary on May 16 and June 3, 2024[84](index=84&type=chunk) - The incentive plan proposed to grant **7.05 million Class I restricted shares** to 50 grantees at a grant price of **4.73 Yuan/share**, with the grant registration completed on July 25, 2024[84](index=84&type=chunk)[85](index=85&type=chunk) - On September 6, 2024, due to the departure of **3 grantees**, the company repurchased and cancelled **0.35 million restricted shares**[86](index=86&type=chunk) - As of the end of the reporting period, the total number of underlying shares involved in all valid equity incentive plans was **6.70 million shares**, accounting for **2.70%** of the company's total share capital at period-end[86](index=86&type=chunk) [IV. Environmental Information Disclosure](index=26&type=section&id=IV.%20Environmental%20Information%20Disclosure) The company and its three major subsidiaries (Zhejiang Qianyuan Haisheng Pharmaceutical Co., Ltd., Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., and Jiangsu Jiayi Pharmaceutical Co., Ltd.) are all listed as legally required environmental information disclosure enterprises and have publicly disclosed their reports on their respective provincial ecological environment department systems - The company and its major subsidiaries, Zhejiang Qianyuan Haisheng Pharmaceutical Co., Ltd., Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., and Jiangsu Jiayi Pharmaceutical Co., Ltd., are all included in the list of enterprises required to disclose environmental information by law[87](index=87&type=chunk) - Each subsidiary has publicly disclosed its reports on the enterprise environmental information disclosure system of the Zhejiang Provincial Ecological Environment Department or Jiangsu Provincial Ecological Environment Department[87](index=87&type=chunk) [V. Social Responsibility](index=26&type=section&id=V.%20Social%20Responsibility) The company demonstrates a strong sense of social responsibility by actively protecting shareholder and creditor rights, safeguarding employee welfare, maintaining commercial integrity with suppliers and consumers, and participating in social welfare initiatives, while ensuring compliant governance and contributing to society - The company strictly abides by laws and regulations, continuously improves its corporate governance structure, and effectively safeguards the legitimate rights and interests of its shareholders and creditors[88](index=88&type=chunk) - The company legally protects employees' legitimate rights and interests, focuses on employee health and safety, establishes a comprehensive compensation management system, and emphasizes talent development and professional quality training[88](index=88&type=chunk) - The company adheres to the business philosophy of "quality first, integrity", achieving mutual benefit with suppliers, customers, and consumers, and providing safe and effective medicines[90](index=90&type=chunk) - The company actively participates in social welfare undertakings, supporting local education, culture, science, health, and employment, caring for vulnerable groups, and paying taxes according to law[90](index=90&type=chunk) [Section V Significant Matters](index=28&type=section&id=Section%20V%20Significant%20Matters) This section covers the fulfillment of commitments by related parties, non-operating fund occupation, illegal external guarantees, auditor appointments, explanations for non-standard audit reports, bankruptcy reorganization, litigation, penalties, integrity status, significant related party transactions, and major contracts [I. Fulfillment of Commitments by Actual Controller, Shareholders, Related Parties, Acquirers, and the Company During the Reporting Period and Unfulfilled Commitments at Period-End](index=28&type=section&id=I.%20Fulfillment%20of%20Commitments%20by%20Actual%20Controller%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%2C%20and%20the%20Company%20During%20the%20Reporting%20Period%20and%20Unfulfilled%20Commitments%20at%20Period-End) During the reporting period, company director and senior management Zhao Qun and senior management Yu Junxian strictly fulfilled their share lock-up commitments from the initial public offering, and commitments under the 2024 restricted stock incentive plan are being normally fulfilled, with no overdue unfulfilled commitments at period-end - Zhao Qun, as a company director and senior management, strictly adhered to the share lock-up commitments made during the initial public offering, with no violations reported as of the end of the reporting period[92](index=92&type=chunk) - Yu Junxian, as a company senior management and other core personnel, strictly adhered to the share lock-up commitments made during the initial public offering, with no violations reported as of the end of the reporting period[92](index=92&type=chunk) - The commitments made by the company and the grantees under the 2024 restricted stock incentive plan are being normally fulfilled[92](index=92&type=chunk) - Commitments fulfilled on time: **Yes**[93](index=93&type=chunk) [II. Non-Operating Fund Occupation by Controlling Shareholders and Other Related Parties of the Listed Company](index=29&type=section&id=II.%20Non-Operating%20Fund%20Occupation%20by%20Controlling%20Shareholders%20and%20Other%20Related%20Parties%20of%20the%20Listed%20Company) During the reporting period, there was no non-operating occupation of the listed company's funds by controlling shareholders or other related parties - During the reporting period, there was no non-operating occupation of the listed company's funds by controlling shareholders or other related parties[94](index=94&type=chunk) [III. Irregular External Guarantees](index=29&type=section&id=III.%20Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[95](index=95&type=chunk) [IV. Appointment and Dismissal of Accounting Firms](index=29&type=section&id=IV.%20Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The company's semi-annual financial report was not audited - The company's semi-annual report was not audited[96](index=96&type=chunk) [V. Explanations by the Board of Directors, Supervisory Board, and Audit Committee Regarding the Accounting Firm's "Non-Standard Audit Report" for the Current Reporting Period](index=29&type=section&id=V.%20Explanations%20by%20the%20Board%20of%20Directors%2C%20Supervisory%20Board%2C%20and%20Audit%20Committee%20Regarding%20the%20Accounting%20Firm's%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Current%20Reporting%20Period) This explanation is not applicable for the current reporting period as the company's semi-annual financial report was not audited - Not applicable[97](index=97&type=chunk) [VI. Board of Directors' Explanation Regarding the "Non-Standard Audit Report" for the Previous Year](index=29&type=section&id=VI.%20Board%20of%20Directors'%20Explanation%20Regarding%20the%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Previous%20Year) This explanation is not applicable for the current reporting period - Not applicable[97](index=97&type=chunk) [VII. Bankruptcy and Reorganization Matters](index=29&type=section&id=VII.%20Bankruptcy%20and%20Reorganization%20Matters) The company had no bankruptcy or reorganization-related matters during the reporting period - The company had no bankruptcy or reorganization-related matters during the reporting period[97](index=97&type=chunk) [VIII. Litigation Matters](index=29&type=section&id=VIII.%20Litigation%20Matters) The company had no significant litigation or arbitration matters, nor any other litigation matters, during the reporting period - The company had no significant litigation or arbitration matters during the reporting period[98](index=98&type=chunk) - The company had no other litigation matters during the reporting period[99](index=99&type=chunk) [IX. Penalties and Rectification](index=30&type=section&id=IX.%20Penalties%20and%20Rectification) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[99](index=99&type=chunk) [X. Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=30&type=section&id=X.%20Integrity%20Status%20of%20the%20Company%2C%20its%20Controlling%20Shareholder%2C%20and%20Actual%20Controller) During the reporting period, there were no issues concerning the integrity status of the company, its controlling shareholder, or its actual controller - During the reporting period, there were no issues concerning the integrity status of the company, its controlling shareholder, or its actual controller[100](index=100&type=chunk) [XI. Significant Related Party Transactions](index=30&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) During the reporting period, the company had no related party transactions related to daily operations, asset or equity acquisitions/disposals, joint external investments, related party creditor-debtor relationships, or other significant related party transactions with affiliated financial companies - The company had no related party transactions related to daily operations during the reporting period[100](index=100&type=chunk) - The company had no related party transactions involving asset or equity acquisitions/disposals during the reporting period[101](index=101&type=chunk) - The company had no related party creditor-debtor relationships during the reporting period[103](index=103&type=chunk) - The company had no other significant related party transactions during the reporting period[106](index=106&type=chunk) [XII. Significant Contracts and Their Fulfillment](index=31&type=section&id=XII.%20Significant%20Contracts%20and%20Their%20Fulfillment) The company had no entrustment, contracting, or leasing matters during the reporting period, but provided several significant guarantees for subsidiaries, totaling **225 million Yuan**, representing **88.72%** of its net assets, and also signed an asset sale contract with Shanxi Shuangyan Pharmaceutical Co., Ltd. for land use rights and properties - The company had no entrustment, contracting, or leasing situations during the reporting period[107](index=107&type=chunk)[108](index=108&type=chunk)[109](index=109&type=chunk) Company's Guarantee Situation for Subsidiaries | Name of Guaranteed Party | Guarantee Limit (10,000 Yuan) | Actual Guarantee Amount (10,000 Yuan) | Guarantee Type | Fulfilled | Related Party Guarantee | | :--- | :--- | :--- | :--- | :--- | :--- | | Zhejiang Qianyuan Haisheng Pharmaceutical Co., Ltd. | 5,000 | 3,200 | Joint and several liability guarantee | Yes | Yes | | Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. | 4,000 | 3,500 | Joint and several liability guarantee | No | No | | Zhejiang Qianyuan Haisheng Pharmaceutical Co., Ltd. | 4,000 | 4,000 | Joint and several liability guarantee | No | No | | Nantong Guangjia Pharmaceutical Co., Ltd. | 15,000 | 15,000 | Joint and several liability guarantee | No | Yes | | **Total Actual Guarantee Balance for Subsidiaries at Period-End** | **23,000** | **22,500** | | | | | **Proportion of Total Actual Guarantee Amount to Company's Net Assets** | | | | | **88.72%** | - The company signed an asset sale contract with Shanxi Shuangyan Pharmaceutical Co., Ltd. to sell land use rights, properties, and attachments for a transaction price of **66.1681 million Yuan**[114](index=114&type=chunk) [XIII. Explanation of Other Significant Matters](index=34&type=section&id=XIII.%20Explanation%20of%20Other%20Significant%20Matters) During the reporting period, the company approved resolutions to revise its Articles of Association, waive pre-emptive rights for Jiayi Pharmaceutical and sign a shareholder agreement, establish the "Operating Management Executive Committee Work Rules" and appoint members, and revise certain management systems, while also noting that accumulated losses have reached one-third of paid-in capital and a "Directors and Senior Management Departure Management System" was formulated - The company approved resolutions to revise the "Articles of Association" and complete industrial and commercial change registration, as well as to waive pre-emptive rights for Jiayi Pharmaceutical and sign a shareholder agreement with new shareholders[116](index=116&type=chunk) - The company approved resolutions including the "2024 Annual Board of Directors' Work Report", "2024 Annual Report and its Summary", and "Company's 2024 Annual Financial Settlement Report"[116](index=116&type=chunk) - The company approved resolutions to formulate the "Operating Management Executive Committee Work Rules", appoint members of the Operating Management Executive Committee, and revise certain company management systems[116](index=116&type=chunk) - The company's accumulated losses have reached **one-third of its paid-in capital**, and it has formulated the "Directors and Senior Management Departure Management System"[117](index=117&type=chunk) [XIV. Significant Matters of Company Subsidiaries](index=34&type=section&id=XIV.%20Significant%20Matters%20of%20Company%20Subsidiaries) During the reporting period, the company's subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., successfully passed its re-certification as a high-tech enterprise - Subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. has successfully passed its re-certification as a high-tech enterprise[118](index=118&type=chunk) [Section VI Share Changes and Shareholder Information](index=35&type=section&id=Section%20VI%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital, securities issuance, shareholder numbers, top ten shareholders, changes in director, supervisor, and senior management shareholdings, and any changes in controlling shareholders or actual controllers [I. Share Capital Changes](index=35&type=section&id=I.%20Share%20Capital%20Changes) During the reporting period, the company's total share capital remained unchanged at **248,318,563 shares**, with an increase of **30,000 restricted shares** due to former Supervisory Board Chairman Zhu Haibo's departure and a corresponding decrease in unrestricted shares, with detailed restricted share information for major shareholders provided Share Capital Changes | Item | Number Before This Change (shares) | Proportion Before This Change | Increase/Decrease in This Change (shares) | Number After This Change (shares) | Proportion After This Change | | :--- | :--- | :--- | :--- | :--- | :--- | | I. Restricted Shares | 23,071,968 | 9.29% | 30,000 | 23,101,968 | 9.30% | | II. Unrestricted Shares | 225,246,595 | 90.71% | -30,000 | 225,216,595 | 90.70% | | III. Total Shares | 248,318,563 | 100.00% | 0 | 248,318,563 | 100.00% | - The reason for the share change is that former Supervisory Board Chairman Mr. Zhu Haibo's shares are **100% locked** for six months after his departure, as he is prohibited from transferring directly or indirectly held company shares during this period[121](index=121&type=chunk) Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period | Restricted Shares Increased in Current Period | Restricted Shares at End of Period | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | Zhao Qun | 10,276,419 | 0 | 10,276,419 | Senior management lock-up shares, 2024 restricted stock incentive lock-up shares | | Huang Lequn | 4,098,795 | 0 | 4,098,795 | Senior management lock-up shares, 2024 restricted stock incentive lock-up shares | | Zhu Haibo | 90,000 | 30,000 | 120,000 | Supervisor lock-up shares | [II. Securities Issuance and Listing](index=37&type=section&id=II.%20Securities%20Issuance%20and%20Listing) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[126](index=126&type=chunk) [III. Number of Shareholders and Shareholding Structure](index=37&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Structure) At the end of the reporting period, the total number of common shareholders was **22,001**, with Weng Zhanguo holding the largest stake at **6.35%**, and Zhao Qun and Huang Lequn acting as parties in concert, while some shareholders held company shares through margin trading and securities lending - The total number of common shareholders at the end of the reporting period was **22,001**[127](index=127&type=chunk) Shareholding of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at End of Reporting Period (shares) | Number of Restricted Shares Held (shares) | Number of Unrestricted Shares Held (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Weng Zhanguo | Domestic Natural Person | 6.35% | 15,772,409 | 0 | 15,772,409 | | Zhao Qun | Domestic Natural Person | 5.52% | 13,701,892 | 10,276,419 | 3,425,473 | | Huang Lequn | Overseas Natural Person | 2.20% | 5,465,060 | 4,098,795 | 1,366,265 | - Among the top 10 common shareholders, shareholders Zhao Qun and Huang Lequn are parties acting in concert[128](index=128&type=chunk) - Some of the top 10 common shareholders held company shares through margin trading and securities lending services[128](index=128&type=chunk) [IV. Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=39&type=section&id=IV.%20Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, there were no significant changes in the shareholdings of the company's directors, supervisors, and senior management, with only the shareholdings of the resigned supervisors Zhu Haibo, Zhang Xuhong, and Zhang Hua recorded, where Zhu Haibo held **120,000 shares** at period-end Changes in Shareholdings of Directors, Supervisors, and Senior Management | Name | Position | Status | Shares Held at Beginning of Period (shares) | Shares Held at End of Period (shares) | | :--- | :--- | :--- | :--- | :--- | | Zhu Haibo | Chairman of Supervisory Board | Resigned | 120,000 | 120,000 | | Zhang Xuhong | Supervisor | Resigned | 0 | 0 | | Zhang Hua | Supervisor | Resigned | 0 | 0 | | **Total** | -- | -- | **120,000** | **120,000** | [V. Changes in Controlling Shareholder or Actual Controller](index=39&type=section&id=V.%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) The company's controlling shareholder and actual controller remained unchanged during the reporting period - The company's controlling shareholder remained unchanged during the reporting period[131](index=131&type=chunk) - The company's actual controller remained unchanged during the reporting period[131](index=131&type=chunk) [VI. Preferred Share Information](index=39&type=section&id=VI.%20Preferred%20Share%20Information) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[131](index=131&type=chunk) [Section VII Bond-Related Information](index=40&type=section&id=Section%20VII%20Bond-Related%20Information) This section confirms that the company had no bond-related matters during the reporting period [Bond-Related Information](index=40&type=section&id=Bond-Related%20Information) The company had no bond-related matters during the reporting period - Not applicable[133](index=133&type=chunk) [Section VIII Financial Report](index=41&type=section&id=Section%20VIII%20Financial%20Report) This section presents the company's unaudited semi-annual financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for both consolidated and parent company levels, along with notes on accounting policies, taxes, and financial risks [I. Audit Report](index=41&type=section&id=I.%20Audit%20Report) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited[135](index=135&type=chunk) [II. Financial Statements](index=41&type=section&id=II.%20Financial%20Statements) This section provides the company's 2025 semi-annual consolidated and parent company financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owners' equity, comprehensively reflecting the company's financial position, operating results, and cash flows at period-end - Financial statements include consolidated balance sheet, parent company balance sheet, consolidated income statement, parent company income statement, consolidated cash flow statement, parent company cash flow statement, consolidated statement of changes in owners' equity, and parent company statement of changes in owners' equity[136](index=136&type=chunk)[140](index=140&type=chunk)[144](index=144&type=chunk)[147](index=147&type=chunk)[151](index=151&type=chunk)[153](index=153&type=chunk)[159](index=159&type=chunk) - Financial statements are denominated in Yuan and prepared as of June 30, 2025[136](index=136&type=chunk) [1. Consolidated Balance Sheet](index=41&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of June 30, 2025, the company's consolidated total assets were **1.496 billion Yuan**, a **3.32% decrease** from the beginning of the period, with total current assets of **456.377 million Yuan**, total non-current assets of **1.040 billion Yuan**, total liabilities of **971.205 million Yuan**, and total owners' equity of **525.175 million Yuan** Consolidated Balance Sheet Key Data | Item | Ending Balance (Yuan) | Beginning Balance (Yuan) | | :--- | :--- | :--- | | Total Assets | 1,496,381,241.42 | 1,547,725,078.17 | | Total Liabilities | 971,205,803.89 | 949,545,094.09 | | Total Owners' Equity Attributable to Parent Company | 253,595,732.99 | 342,998,882.45 | | Minority Interests | 271,579,704.54 | 255,181,101.63 | | Total Owners' Equity | 525,175,437.53 | 598,179,984.08 | - Monetary funds ending balance: **92,408,396.19 Yuan**, accounts receivable: **132,674,931.36 Yuan**, inventories: **149,943,038.52 Yuan**[137](index=137&type=chunk) - Short-term borrowings ending balance: **130,919,141.55 Yuan**, long-term borrowings: **167,000,000.00 Yuan**, long-term payables: **226,336,400.00 Yuan**[138](index=138&type=chunk)[139](index=139&type=chunk) [2. Parent Company Balance Sheet](index=43&type=section&id=2.%20Parent%20Company%20Balance%20Sheet) As of June 30, 2025, the parent company's total assets were **1.524 billion Yuan**, an increase from the beginning of the period, with total current assets of **200.390 million Yuan**, total non-current assets of **1.324 billion Yuan**, total liabilities of **827.584 million Yuan**, and total owners' equity of **696.839 million Yuan** Parent Company Balance Sheet Key Data | Item | Ending Balance (Yuan) | Beginning Balance (Yuan) | | :--- | :--- | :--- | | Total Assets | 1,524,423,559.24 | 1,488,814,963.55 | | Total Liabilities | 827,584,033.91 | 792,107,634.01 | | Total Owners' Equity | 696,839,525.33 | 696,707,329.54 | - Monetary funds ending balance: **32,771,942.44 Yuan**, accounts receivable: **90,973,567.15 Yuan**, long-term equity investments: **1,236,720,407.04 Yuan**[141](index=141&type=chunk) - Other payables ending balance: **612,550,448.96 Yuan**, non-current liabilities due within one year: **127,125,973.21 Yuan**[142](index=142&type=chunk) [3. Consolidated Income Statement](index=46&type=section&id=3.%20Consolidated%20Income%20Statement) For the first half of 2025, the company's consolidated total operating revenue was **372.995 million Yuan**, a **7.01% year-on-year decrease**, resulting in a net profit of **16.333 million Yuan** and net profit attributable to parent company shareholders of **0.380 million Yuan**, a significant **98.86% year-on-year decrease**, with basic earnings per share of **0.0016 Yuan/share** Consolidated Income Statement Key Data | Item | H1 2025 (Yuan) | H1 2024 (Yuan) | | :--- | :--- | :--- | | I. Total Operating Revenue | 372,995,932.54 | 401,112,573.00 | | III. Operating Profit (Loss indicated by "-") | 30,969,258.94 | 41,350,311.02 | | IV. Total Profit (Total loss indicated by "-") | 35,563,602.22 | 50,631,899.44 | | V. Net Profit (Net loss indicated by "-") | 16,333,500.92 | 49,085,401.93 | | 1. Net Profit Attributable to Parent Company Shareholders (Net loss indicated by "-") | 380,868.67 | 33,502,484.50 | | VIII. Earnings Per Share: (I) Basic Earnings Per Share | 0.0016 | 0.1387 | - Income tax expense for the current period was **19,230,101.30 Yuan**, a significant increase from **1,546,497.51 Yuan** in the prior year period[146](index=146&type=chunk) [4. Parent Company Income Statement](index=48&type=section&id=4.%20Parent%20Company%20Income%20Statement) For the first half of 2025, the parent company's operating revenue was **70.984 million Yuan**, a **17.17% year-on-year decrease**, resulting in an operating profit of

证券代码：300254 证券简称：仟源医药 公告编号：2025-054 山西仟源医药集团股份有限公司 关于召开2025年第四次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 9 日在 巨潮资讯网发布了《关于召开 2025 年第四次临时股东会的通知》（公告编号： 2025-053）。公司定于 2025 年 8 月 26 日（星期二）以现场表决与网络投票相结 合的方式召开 2025 年第四次临时股东会。现将会议有关事项再次提示如下： 一、召开会议基本情况 1、股东会届次：2025 年第四次临时股东会 2、股东会的召集人：公司第五届董事会 3、会议召开的合法性及合规性：董事会召开本次股东会会议符合《公司法》、 《证券法》、《深圳证券交易所创业板股票上市规则》、《上市公司股东会规则》 等有关法律、法规、规则以及《公司章程》的规定。 网络投票时间为： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 8 月 26 日 9:15-9：25，9：30-11 ...

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]